PATENT CLAIM ANALYSIS

Application Number: 15909787
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2019-03
Patent Classification: ["424", "152100"]

Abstract:
Disclosed herein are methods of preventing incidence of a migrainous or non-migrainous post-ictal headache, and/or at least one secondary symptom associated with a migrainous post-ictal headache in a subject comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed methods are also provided.

Claim (Index 39):
The method of  claim 1 , wherein the monoclonal antibody is administered prior to a seizure.

Metadata:
- Claim Count in Document: 55.0
- Percentile: 90.0
- Lexical Diversity: 1.34146
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14711705', '15879900', '14664715', '15712444', '14719015']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5913757236086121
- 35 USC 102 Novelty (BERT): 0.5926798471304525
- Combined Prediction Score: 0.5915061359607963
- Mean Citation Score: 492.9413579999999
- Max Citation Score: 507.0279
- Similarity Product: 419.2361687221169

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test